Two Patients With Severe Autoimmune Disease Hit 15 Years of Remission After a Single Stem Cell Transplant

Two people with a rare, potentially fatal autoimmune disease that had stopped responding to every available medication have now gone more than 15 years without a single relapse, following a procedure that completely replaced their immune systems. The findings, reported in the journal Med by neurologist Massimo Filippi and colleagues at IRCCS San Raffaele Hospital in Milan, represent what the authors describe as the first use of allogeneic haematopoietic stem-cell transplantation to treat neuromyelitis optica spectrum disorder. While the sample size is just two, the duration of the outcomes is striking enough to push the field toward a larger clinical trial.

Neuromyelitis Optica Spectrum Disorder and Its Immune System Roots

Neuromyelitis optica spectrum disorder, or NMOSD, is not a well-known condition outside specialist neurology, but its consequences are severe. Immune cells produce a specific type of antibody, called anti-aquaporin-4 (AQP4-IgG), that attacks the spinal cord and the optic nerve connecting the eye and brain. The result is a cycle of inflammatory attacks that can cause eye pain, vision loss, vomiting, and weakness or paralysis of the limbs. Standard treatment focuses on suppressing these attacks with ongoing medication, but for a subset of patients, none of the available options work.

The microbiome connection matters here, even if it sits slightly offstage in this particular study. The immune cells responsible for NMOSD pathology, particularly the B cells that manufacture AQP4-IgG antibodies and the regulatory T cells that fail to keep them in check, are shaped throughout life by gut microbial signals. Research into how gut bacteria influence B cell maturation and autoimmune tolerance has grown considerably in the past decade, and dysregulation in those microbial-immune conversations is increasingly seen as a background factor in conditions like NMOSD. The transplant described here essentially bypasses that entire system by replacing the immune cell population wholesale.

Complete Immune Reconstitution After a Single Infusion

The procedure Filippi's team used is called an allogeneic haematopoietic stem-cell transplant. In this approach, stem cells are collected from a donor's blood rather than the patient's own body, which is the key distinction from autologous versions of the treatment. The first patient, a man, received cells from his sister in 2009; the second, a woman, received cells from an unrelated donor in 2010. Before either infusion, both patients underwent chemotherapy with fludarabine and treosulfan to destroy their existing immune cells, and received a monoclonal antibody drug specifically to eliminate B cells, the very population producing the damaging AQP4-IgG antibodies. A short course of immunosuppressants followed to reduce the risk of graft-versus-host disease, a potentially life-threatening complication in which the donor immune system attacks the recipient's body.

The outcomes over the following 15-plus years were remarkable for a disease this severe. The man's neurological function improved to the point where he resumed normal daily life and has since had two children. The woman gained substantially more effective use of her arms and no longer requires any symptom-reducing medication. Critically, neither patient developed NMOSD-associated antibodies after the transplant. Both built entirely new immune systems of donor origin, with the pathogenic B cell populations replaced.

Why a Two-Patient Study Still Generates Serious Scientific Interest

A case series of two people would ordinarily receive limited attention, but the 15-year follow-up duration and the completeness of immune reconstitution make this report genuinely unusual. The methodology had to balance aggressive enough conditioning to eradicate a self-attacking immune system against the real danger of the transplant itself. The chemotherapy regimen and B-cell-depleting antibody together created space for donor cells to engraft without the pathogenic population reasserting itself, which is the specific mechanism the researchers point to as the likely driver of remission.

The choice to use allogeneic rather than autologous cells, where a patient's own stem cells are collected and reinfused, is also deliberate. Filippi's team notes that autologous transplants may be less effective in NMOSD precisely because any residual B cells in the patient's own harvested material could reintroduce the disease. Donor cells carry no such legacy. This reasoning is consistent with emerging evidence on facilitating durable clinical responses in autoimmune conditions, where the completeness of immune cell eradication appears to correlate with remission depth.

Significant Risks and the Questions That Remain

Scientists working in this space are cautious, and deliberately so. Jiao Jiao Li, a biomedical engineer at the University of Technology Sydney who commented on the findings, put it plainly: "I don't think we can say it's a cure, but then again, it has addressed the problem the disease has caused over this very long period of time." Graft-versus-host disease remains a real and serious risk with any allogeneic transplant, as does vulnerability to infection during the period when the immune system is essentially absent. Both patients received prophylactic treatment, but the window between conditioning and full engraftment is genuinely dangerous.

Translating this approach into broader clinical practice also faces hurdles that go beyond biology. Barriers to clinical research translation in rare disease settings typically include limited patient numbers, absence of controlled comparison groups, and institutional reluctance to adopt high-risk procedures based on small case series, all of which apply here. The researchers are explicit: a larger clinical trial is needed before any conclusions about population-level efficacy can be drawn.

What Comes Next for NMOSD and Immune System Replacement

Filippi and colleagues suggest the procedure could be considered specifically for younger patients who have severe, treatment-refractory disease and who have not responded to conventional therapies. That framing is appropriately conservative for what is, at this stage, preliminary evidence from two cases. The 15-year remission window does, however, shift the conversation in a meaningful way: the question is no longer whether durable outcomes are possible in principle, but whether the risk-benefit ratio can be validated across a larger cohort.

The deeper implication for autoimmune neurology is that conditions driven by specific, pathogenic immune cell populations may be amenable to the kind of root-cause reset that oncology has used for decades. NMOSD is rare, but the logic of replacing a self-attacking immune system rather than indefinitely suppressing it applies to a broader category of disease. The gut-immune axis that shapes those cell populations throughout life remains a parallel avenue of investigation, one that may eventually inform both who is most likely to relapse and how donor immune systems adapt to the gut microbial environment they inherit.

Evidence rating

INVESTIGATIONAL — 51/100

Two-patient uncontrolled case series with no comparison group and no replication. Reports long-term remission outcomes but cannot establish causation or generalizability at this sample size. The authors themselves decline to characterize the outcome as a cure, and a larger clinical trial has not yet been conducted.

References

1. Client Challenge. https://doi.org/10.1038/d41586-026-01925-7
2. Barriers to translation of research. NIH. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3653139/
3. Hammoda Abu‐Odah, Nizar B. Said, Satish Chandrasekhar Nair, et al. (2022). Identifying barriers and facilitators of translating research evidence into clinical practice: A systematic review of reviews. Health & Social Care in the Community. https://doi.org/10.1111/hsc.13898
4. Hammoda Abu‐Odah, Nizar B. Said, Satish Chandrasekhar Nair, et al. (2022). Identifying barriers and facilitators of translating research evidence into clinical practice: A systematic review of reviews. Health & Social Care in the Community. https://doi.org/10.1111/hsc.13898